Ofev (nintedanib) reduced lung function decline by more than 50% in patients with progressive fibrosing interstitial lung diseases (ILDs), data from a Phase 3 trial show. The findings were presented in a poster at the recent European Respiratory Society (ERS) International Congress in Madrid, Spain, and simultaneously…
Blade Therapeutics will expand its pipeline in the field of fibrotic diseases with the acquisition of Atxco and its lead candidate PAT-409, which is ready to enter Phase 1 clinical studies. PAT-409 was engineered to specifically inhibit the autotaxin enzyme involved in the production of a fatty molecule called…
Learning to live with a life-threatening, chronic lung disease as a young adult is the hardest thing I’ve ever done. Idiopathic pulmonary fibrosis (IPF) is characterized by irreversible and progressive scarring of the lungs, known as “fibrosis,” which ultimately diminishes a person’s ability to breathe. While the prognosis of IPF…
Blocking the activity of interleukin-11 (IL-11) — a molecule that mediates immune and inflammatory responses — reverses tissue scarring, or fibrosis, in the lungs of mice with idiopathic pulmonary fibrosis (IPF), a study has found. The findings of the study, “Interleukin-11 is a therapeutic target in idiopathic…
When my mom, Holly, was hospitalized to wait for a double-lung transplant, I needed to talk to a survivor. I longed to hear from someone who had been through it and was living, breathing proof that surviving was possible. About a year before my mom…
Different combinations of medications to manage comorbidities (additional conditions) may influence disease progression in people with idiopathic pulmonary fibrosis (IPF), a study suggests. The study, “Concomitant Medications and Clinical Outcomes in Idiopathic Pulmonary Fibrosis,” was published in the European Respiratory Journal. IPF is a complex…
Next month’s annual conference of the National Organization for Rare Disorders (NORD) in Washington, D.C., couldn’t come at a better time, says Marshall Summar, MD, chairman of NORD’s board of directors. “The pace of discovery in rare diseases has gone from brisk to hypersonic,” Summar told Bionews Services, publisher…
I’m sure that you’re familiar with the saying, “Time heals all things.” I don’t believe this is true of the grieving process. A year ago, I was texting with my friend and colleague Serena Lawrence about the terrible news she had recently received. Serena told me that she was dying…
Information about pulmonary fibrosis (PF) can be hard to find. This article aims to answer some of the frequently asked questions (FAQs) about this disease. What is PF? PF belongs to a group of lung disorders called interstitial lung diseases (ILD). It is a progressive disease marked by…
A small RNA molecule called miR-133a can prevent tissue scarring (fibrosis) in people with idiopathic pulmonary fibrosis (IPF) by interfering with a pro-fibrotic signaling pathway that is involved in disease progression, a study says. The findings of the study, “Transforming growth factor (TGF)-β1-induced miR-133a inhibits myofibroblast differentiation…
Get regular updates to your inbox.
